Abstract
Omentin-1 and prostate specific antigen (PSA) are known to be markers of insulin resistance and hyperandrogenism respectively in polycystic ovary syndrome (PCOS). This study aimed to assess the changes in serum omentin-1 and PSA levels in PCOS patients while on treatment. Serum omentin-1, PSA, BMI and Ferriman gallwey score (FG score) were measured in 80 women with PCOS. The subjects were treated depending on their presenting complaints. The parameters were analysed at baseline and after 3months of treatment viz. lifestyle modification (Group I), oral contraceptive pills (OCP) (Group II), clomiphene citrate (Group III), medroxy progesterone acetate (Group IV) or metformin (Group V) and was compared using paired-t test. Group II showed significant increase in serum omentin-1 (271.7±112.2 vs 378.1±242ng/ml; P=0.025) and decrease in serum PSA (0.014±0.02 vs 0.005±0.008ng/ml; P=0.027) after 3 cycles of OCP. Group I and IV also showed a decrease in serum PSA while FG score decreased in group II and group III. There was a negative correlation observed between serum omentin-1 and BMI. To conclude, PCOS women showed increase in serum omentin-1 levels after 3 cycles of OCP while serum PSA decreased after 3months of lifestyle modification or on treatment with OCP or medroxy progesterone acetate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
